Skip to main content

Retatrutide Dosing Explained: 1, 4, 8 and 12 mg (2026)

Last updated: June 25, 2026  |  Written by: Eric Sornoso, MealFan editor  |  Sources: Eli Lilly TRIUMPH-1 topline, NEJM Phase 2, SURMOUNT/STEP trials, FDA status June 2026.

Not medical advice. Retatrutide is investigational and not FDA approved as of June 2026. This is an editorial summary of public trial data. Consult a licensed clinician.
Short answer. In the trials, retatrutide was given as a once-weekly injection and titrated up gradually — starting around 1 mg and stepping up over weeks to a target of 4, 8, or 12 mg. The 12 mg dose drove the biggest weight loss. Slow escalation is what keeps nausea manageable. (These are trial protocols; there is no approved dosing yet.)
Gradual dose escalation (trial schedule)1 mgstart4 mgwk 4+8 mgwk 8+12 mgtarget
Representative trial escalation. Final approved dosing will be set by the FDA label.

Key takeaways

  • Trials used a weekly injection titrated from ~1 mg up to 4, 8, or 12 mg.
  • The 12 mg dose drove the largest weight loss.
  • Slow escalation keeps nausea manageable – never rush doses.
  • No FDA-approved dose exists yet; it remains investigational.

How dosing worked in the trials

Retatrutide was studied as a weekly subcutaneous injection. Participants started low and increased the dose every few weeks to let the body adjust. The headline results came from the 12 mg target dose, where average weight loss reached roughly 24–28% at 80 weeks.

Why escalate slowly?

Stepping the dose up gradually is the single biggest lever for tolerability across this whole drug class. Most nausea, vomiting, and diarrhea cluster in the first weeks after each increase, then settle. Jumping to a high dose too fast makes side effects worse without improving results.

Dose (trial) Role
1 mg Starting dose, adjustment
4 mg Intermediate step
8 mg Higher maintenance option
12 mg Top dose, largest weight loss
No approved dosing exists yet. The numbers above are trial protocols, not a prescription. Final dosing will be set by the FDA label if/when retatrutide is approved (realistically 2027–2028).

FAQ

What doses of retatrutide were studied?

Trials used a weekly injection titrated from about 1 mg up to target doses of 4, 8, or 12 mg, with 12 mg producing the largest weight loss.

Is there an official retatrutide dose?

No. It is investigational, so there is no FDA-approved dosing yet. Approved dosing would be set on the label after approval.

Why start at a low dose?

Slow escalation minimizes nausea and other GI side effects, which cluster after each dose increase and then ease.

Why titration schedules exist

Starting low and stepping up isn’t caution for its own sake – it’s the single biggest lever for tolerability in this entire drug class. Side effects cluster right after each increase, so a gradual climb lets the gut adapt between steps. Rushing to a high dose makes people miserable without improving the end result.

What happens if you escalate too fast

Jumping doses tends to trigger the worst of the nausea, vomiting, and diarrhea, and it’s the most common reason people abandon GLP-1 treatment early. Slower is almost always the smarter path, even if the scale moves a little later.

How dosing compares across the class

Drug Form Pattern
Retatrutide (trial) Weekly injection Titrate ~1 mg up to 4/8/12 mg
Semaglutide Weekly injection / daily pill Titrate up to 2.4 mg (Wegovy)
Tirzepatide Weekly injection Titrate up to 15 mg

A note on missed doses

General guidance across weekly GLP-1 injectables is to take a missed dose within a couple of days, or skip it and resume the schedule if it’s been longer – never double up. Retatrutide’s exact instructions will come from the FDA label if it’s approved. Until then, there is no at-home retatrutide to dose.

The nutrition side most drug guides skip

We are a food site, so here is what the drug-only sites leave out: retatrutide works by shrinking appetite, and that creates a real nutritional risk. When you eat far less, you do not just lose fat – you can lose muscle and fall short on protein, fiber, and key vitamins and minerals. The fix is not eating more; it is making every bite count.

The four risks to manage (and the food fix)

Nutrition risk Why it happens The food fix
Muscle & protein loss Rapid weight loss plus too little protein – up to a third of lost weight can be lean muscle. 1.2-1.6 g protein per kg body weight daily; anchor every meal and snack with protein.
Low micronutrients Eating far less total food shrinks intake of iron, B12, calcium, vitamin D, potassium and magnesium. Nutrient-dense picks: eggs, salmon/sardines, Greek yogurt, leafy greens, beans, nuts and seeds, fortified foods.
Constipation Slowed digestion plus less food and fiber. Fiber-rich vegetables and fruit you can tolerate; steady fluids; move daily.
Dehydration & low energy Reduced intake and GI fluid losses during dose changes. Sip fluids and electrolytes through the day; never skip food entirely.

What to actually eat on retatrutide

  • Protein at every meal and snack: eggs, chicken, fish, Greek yogurt, cottage cheese, tofu, beans, or a protein shake. When you can only finish a few bites, make them protein.
  • Nutrient-dense, smaller-volume foods: salmon and sardines (omega-3, vitamin D, B12), eggs, dairy, leafy greens, beans and lentils, nuts and seeds, berries.
  • Easy formats for nausea days: protein smoothies (protein powder + fruit + spinach), broth-based soups, yogurt.
  • Hydration and fiber: water and electrolytes through the day, plus tolerable high-fiber vegetables and fruit to keep things moving.

If your appetite is so low that you are eating very little, a daily multivitamin can backstop the gaps – ask your prescribing clinician. The goal across the board: protect muscle and stay nourished while the medication does its job.

The simplest way to hit these numbers while your appetite is unpredictable is pre-portioned, macro-labeled meal delivery built for exactly this.

See our tested GLP-1 meal delivery picks →
Or browse Best High-Protein Meal Delivery

Sources & references

Figures reflect Eli Lilly topline disclosures and peer-reviewed trial publications as of June 25, 2026. Retatrutide remains investigational; we will update on FDA action. Not medical advice.

Write a review × Browse menu
Write a review × Browse menu